The KIN-FAST Trial (KIN001 For Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With SARS-CoV-2

Exclusion Criteria

• •1. Patients with an indication for hospitalization (e.g. SpO2 \<92%)
• •2. Patients participating in another clinical trial with a new investigational drug or investigational non-drug treatment
• •3. Known allergy or intolerance to pamapimod or any other ingredient of the IMP or another P38 inhibitor
• •4. Known allergy or intolerance of clinical relevance to pioglitazone or any other ingredient of the IMP.
• •5. Patients where oral administration of pioglitazone is contraindicated (i.e. cardiac failure or history of cardiac failure (NYHA stages I to IV), with hepatic impairment, diabetic ketoacidosis, current bladder cancer or a history of bladder cancer, uninvestigated macroscopic haematuria
• •6. Any use of CYP450 2C8 inducers (e.g. rifampicin)
• •7. Known or suspected active viral (including HIV, hepatitis B, hepatitis C), bacterial, mycobacterial or fungal infection other than COVID-19. Virologic testing not required unless infection is suspected.
• •8. Pregnant or breastfeeding women
• •9. Any uncontrolled concurrent illness that would put the patient at a greater risk or limit compliance with the study requirements as determined at the discretion of the investigator
• •10. Liver enzyme elevation more than 3x above normal in the last 4 weeks or at inclusion
• •11. Patients who are detained or committed to an institution by a law court or by legal authorities (subject is vulnerable, such as deprived of freedom)